Skinvisible, Inc. (SKVI)
Consumer Defensive · OQB
Fundamentals
Valuation and ratings
Skinvisible, Inc. trades at USD0.20. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 30 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
SKVI dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
About Skinvisible, Inc.
Skinvisible, Inc. focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its flagship product, Invisicare, is a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. The company also offers non-dermatological formulations for women's health, pain management, and other markets. In addition, it engages in the development and licensing of topical prescription and over-the-counter products, as well as the co-development of formulations for pharmaceutical clients. Further, the company provides solutions to pharmaceutical companies by reformulating products coming off patent with a new Invisicare patent, and new product benefits and line extensions. It has a licensing and collaboration agreement with Ovation Science for the use of Invisicare technology with cannabinoids for topical/transdermal products, including new formulations with THC-V targeting obesity and metabolic health. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.
The full research page for SKVI, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.